Egypt Retinal Disease Drugs Market Industry Trends and Forecast to 2034: Segmented by (Drug, Indication, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034
Overview
Market Dashboard
Egypt · 2024–2034 · placeholder estimates
Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the
full report.
Estimate 2024$42.8 MnPlaceholder estimate
Estimate 2025$46.0 Mn0.3% of the global market
Projected 2034$89.8 Mn 95%Adds $43.7 Mn over 9 forecast years
CAGR 2025–20347.7%Faster than 27% of 180 Pharmaceuticals markets here
Key players5
Egypt is 0.27% of the global market.
In Africa, the largest is South Africa at $116.4 Mn.
Fastest growing: Egypt (this report) at 7.7% a year.
Egypt ranks 2nd of 3 by size in Africa.
Market size projection
Egypt
Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.
Value added each year
$43.7 Mn total, 2026–2034
Year-by-year market size, 2024–2034
Retinal Disease Drugs Market market size by year, Egypt
Year
Market size
Change that year
Since 2025
2024 (estimate)
$42.8 Mn
—
—
2025 (base)
$46.0 Mn
+$3.3 Mn
—
2026 (forecast)
$49.6 Mn
+$3.5 Mn
+7.7%
2027 (forecast)
$53.4 Mn
+$3.8 Mn
+16%
2028 (forecast)
$57.5 Mn
+$4.1 Mn
+24.9%
2029 (forecast)
$62.0 Mn
+$4.4 Mn
+34.5%
2030 (forecast)
$66.7 Mn
+$4.8 Mn
+44.9%
2031 (forecast)
$71.9 Mn
+$5.1 Mn
+56.1%
2032 (forecast)
$77.4 Mn
+$5.5 Mn
+68.1%
2033 (forecast)
$83.4 Mn
+$6.0 Mn
+81%
2034 (forecast)
$89.8 Mn
+$6.4 Mn
+95%
Placeholder estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.
Key segments of the retinal Disease Drugs market include drug (Aflibercept, Faricimab and Ranibizumab) and indication (Wet AMD, Diabetic Macular Edema and Retinal Vein Occlusion).
Egypt Retinal Disease Drugs market size, 2024–2034. Placeholder estimates; researched figures come with the full report. Source: Acuitas Health Analytics.
Egypt Retinal Disease Drugs Market Dynamics
Market Growth Drivers
An ageing population, more people with diabetes and long-term conditions, better treatments and wider access to specialist care are driving the retinal Disease Drugs market.
Opportunity
Longer-acting treatments, home-based care and screening in emerging markets give the retinal Disease Drugs market room to grow.
Market Restraints
High costs of new treatments, specialist shortages, low awareness and limited reimbursement in some countries hold back the retinal Disease Drugs market.
Competitive Landscape for Retinal Disease Drugs Market in Egypt
The retinal Disease Drugs market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.
Healthcare Policies and Regulatory Landscape for Retinal Disease Drugs Market in Egypt
Retinal Disease Drugs in Egypt: rules, payment and research
Medicines are registered with the Egyptian Drug Authority (EDA), set up in 2019.[1] A universal health insurance system, set up by Law No. 2 of 2018, is being rolled out governorate by governorate, starting with Port Said in 2019.[2] ClinicalTrials.gov lists 3 studies on Retinal Disease Drugs that are recruiting, active or about to start in Egypt.[3]
[3]ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Egypt. Retrieved 12 Nov 2026.
Policy changes and Reimbursement scenario
Regulators such as the US FDA, the European Medicines Agency and national drug authorities set approval, pricing and safety rules for retinal Disease Drugs. Reimbursement decisions by public payers and insurers shape how fast new therapies reach patients in Egypt.
2.2 Market Size, Growth Prospects and Key findings
3 Market Dynamics
3.1 Market Growth Drivers Analysis
3.2 Market Restraints Analysis
4 Market Segmentation
4.1 By Drug
4.2 By Indication
4.3 By End User
5 By Market Share
5.1 Market Analysis, Insights and Forecast – By Revenue
6 Competitive Landscape
6.1 Major Top Market Players Products in Pipeline
6.2 R&D Initiatives
6.3 Notable recent Deals
6.3.1 Strategic Divestments
6.3.2 Mergers & Acquisitions
6.3.3 Partnerships
6.3.4 Joint Ventures
7 Key Company Profiles
7.1 Regeneron Pharmaceuticals
7.2 Roche
7.3 Bayer AG
7.4 Novartis
7.5 Samsung Bioepis
8 Healthcare Policies and Regulatory Landscape
8.1 Policy changes and Reimbursement scenario
8.2 Government Initiatives / Intervention programs
The retinal Disease Drugs market can be segmented based on various criteria, including drug, indication and end user. Here's a breakdown of the market segmentation
Other companies that free public records show in this market: trials they lead, US approvals and WHO prequalification. They are not part of our key players research. Each count opens its source.
Also active in this area, from free public records
Source: ClinicalTrials.gov, Active studies (recruiting, about to start or running) each company leads, found with this market's trial search, worldwide. Retrieved 13 Nov 2026.
Source: Drugs@FDA, US approvals each company holds for medicines on the market whose FDA label lists this use. Retrieved 13 Nov 2026.
Beyond the market numbers
Research, trials and patients
What doctors and scientists are doing in Retinal Disease Drugs right now, from free public sources.
Sources:PubMed (US National Library of Medicine),
ClinicalTrials.gov,
World Bank.
Fetched 12 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.
Public data, with sources
Retinal Disease Drugs in context
Egypt compared
Health spending per person: 141 US$ per person (2023). World: 1,317 US$ per person (2023). 3rd highest of the 17 countries we cover in Africa.[1]
Doctors: 0.67 per 1,000 people (2020). World: 1.86 per 1,000 people (2022). 3rd highest of the 17 countries we cover in Africa.[2]
People aged 65 and over: 5.3% of people (2025). World: 10.4% of people (2025). 3rd highest of the 17 countries we cover in Africa.[3]
[1]World Bank Open Data, Health spending per person (US$ per person). Retrieved 17 Nov 2026.
How big is the Retinal Disease Drugs market in Egypt?
Placeholder estimate: about $46.0 Mn in 2025, rising to about $89.8 Mn by 2034. These are early estimates, not researched figures; the researched values come with the full report.
How fast is the Retinal Disease Drugs market in Egypt growing?
Placeholder estimate: about 7.7% a year (CAGR, 2025–2034). The researched growth rate comes with the full report.
What segments does the Retinal Disease Drugs market report cover?
The report splits the market by drug (Aflibercept, Faricimab, Ranibizumab, Biosimilars), indication (Wet AMD, Diabetic Macular Edema, Retinal Vein Occlusion) and end user (Hospitals, Specialty Clinics, Retail Pharmacies, Online Pharmacies).
Who are the key players in the Retinal Disease Drugs market?
Key players include Regeneron Pharmaceuticals, Roche, Bayer AG, Novartis AG and Samsung Bioepis.
What is driving the Retinal Disease Drugs market?
An ageing population, more people with diabetes and long-term conditions, better treatments and wider access to specialist care are driving the retinal Disease Drugs market.
Who regulates Retinal Disease Drugs in Egypt?
Medicines are registered with the Egyptian Drug Authority (EDA), set up in 2019. Source: Egyptian Drug Authority. Checked 14 Nov 2026.
How is healthcare paid for in Egypt?
A universal health insurance system, set up by Law No. 2 of 2018, is being rolled out governorate by governorate, starting with Port Said in 2019. Source: Universal Health Insurance Authority. Checked 14 Nov 2026.
How many clinical trials on Retinal Disease Drugs are running in Egypt?
3 studies are recruiting, active or about to start in Egypt, according to ClinicalTrials.gov. Source: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Egypt. Retrieved 12 Nov 2026.
How much research is published on Retinal Disease Drugs?
PubMed lists 1,099 papers on Retinal Disease Drugs added since January 2021, worldwide. Source: PubMed, Papers added since 1 January 2021 matching this market. Retrieved 12 Nov 2026.